Walleye Capital
DSGN icon

Walleye Capital’s Design Therapeutics DSGN Stock Holding History

Walleye Capital’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-141,127
Closed -$871K – 4431
2024
Q4 		$871K Buy
141,127
+71,127
+102% +$412K ﹤0.01% 2502
2024
Q3 		$377K Buy
70,000
+9,788
+16% +$46K ﹤0.01% 3553
2024
Q2 		$202K Sell
60,212
-134,339
-69% -$523K ﹤0.01% 4294
2024
Q1 		$784K Sell
194,551
-167,836
-46% -$448K ﹤0.01% 2817
2023
Q4 		$960K Sell
362,387
-11,126
-3% -$25.5K ﹤0.01% 2381
2023
Q3 		$881K Buy
373,513
+362,375
+3,254% +$1.69M ﹤0.01% 2348
2023
Q2 		$70.2K Buy
+11,138
New +$68.2K ﹤0.01% 3544
2023
Q1 		– Sell
-10,703
Closed -$110K – 4019
2022
Q4 		$110K Buy
+10,703
New +$145K ﹤0.01% 2328

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital's DSGN Position: Q1 2025 in Review

Walleye Capital sold out of Design Therapeutics (DSGN) in Q1 2025, closing a stake of 141,127 shares — an estimated $871K sold.

Walleye Capital first reported a position in DSGN in Q4 2022 and held it in 8 quarters. The position peaked at $960K in Q4 2023. 98 funds tracked by Wall St. Rank hold DSGN as of Q1 2025.

  • Walleye Capital reported no remaining Design Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 141,127 Design Therapeutics shares in Q1 2025, an estimated $871K.
  • Walleye Capital first reported a position in Design Therapeutics in Q4 2022 and held it in 8 quarters.
  • Walleye Capital's Design Therapeutics position peaked at $960K in Q4 2023.
  • 98 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.